BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Arrayit Corporation to Spin-Off Arrayit Diagnostics to Shareholders


12/14/2011 7:10:48 AM

SUNNYVALE, Calif.--(BUSINESS WIRE)--Arrayit Corporation (OTCBB: ARYC - News) has approved the spin-off of its majority owned subsidiary, Arrayit Diagnostics, Inc. Arrayit Corporation will distribute to its existing shareholders its 78.18% interest in Arrayit Diagnostics as a stock dividend. The stock dividend distribution date and further details are expected to be announced early in the first quarter of 2012.

Since July of 2009, Arrayit Diagnostics has operated as an independent entity of Arrayit Corporation and will continue to hold all the intellectual property, licenses and development agreement assets related to the ovarian cancer pre-symptomatic diagnostic test known as OvaDx®. Arrayit Diagnostics expects to be listed on the OTCBB. John Howell, the current CEO and President, will continue in that capacity, focusing on the approval process with the FDA and establishing strategic relationships for marketing of the test. “Operating as a separate public entity will enable Arrayit Corporation to focus on its core business of advanced equipment sales and manufacturing for the life sciences, while simultaneously allowing Arrayit Diagnostics the opportunity to fully commercialize its ovarian cancer diagnostic technology,” states Howell.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit www.arrayit.com for more information.

About Arrayit Diagnostics

Arrayit Diagnostics, headquartered in Redmond, Oregon, is leading the research and approval process of the pre-symptomatic ovarian cancer test, OvaDx, based on molecular diagnostic technology.

Safe Harbor Statement

We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2011.

Contacts

Arrayit Corporation

Celeste Wade, 408-744-1331

Investor Relations

investorinfo@arrayit.com

www.arrayit.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->